Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

BACKGROUND: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are un...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsubata, Yukari, Watanabe, Kana, Saito, Ryota, Nakamura, Atsushi, Yoshioka, Hiroshige, Morita, Mami, Honda, Ryoichi, Kanaji, Nobuhiro, Ohizumi, Satoshi, Jingu, Daisuke, Nakagawa, Taku, Nakazawa, Kensuke, Mouri, Atsuto, Takeuchi, Susumu, Furuya, Naoki, Akazawa, Yuki, Miura, Kiyotaka, Ichihara, Eiki, Maemondo, Makoto, Morita, Satoshi, Kobayashi, Kunihiko, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732858/
https://www.ncbi.nlm.nih.gov/pubmed/34643820
http://dx.doi.org/10.1007/s10147-021-02043-2

Ejemplares similares

Ejemplares similares